Yahoo
Tokyo - Delayed Quote JPY

Astellas Pharma Inc. (4503.T)

2,571.00 +58.00 (+2.31%)
At close: October 30 at 3:30:00 PM GMT+9
View in AlphaSpace Currency in JPY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
3/31/2026
3/31/2025
3/31/2024
3/31/2023
Total Revenue
2,274,365,000
2,139,245,000
1,912,323,000
1,603,672,000
1,518,619,000
Cost of Revenue
436,299,000
408,426,000
349,206,000
292,485,000
288,353,000
Gross Profit
1,838,067,000
1,730,820,000
1,563,117,000
1,311,187,000
1,230,266,000
Operating Expense
1,365,195,000
1,350,761,000
1,522,869,000
1,292,240,000
1,098,709,000
Operating Income
472,872,000
380,059,000
40,248,000
18,947,000
131,557,000
Net Non Operating Interest Income Expense
194,000
-6,046,000
-9,803,000
-550,000
-669,000
Pretax Income
472,685,000
376,587,000
31,237,000
24,969,000
132,361,000
Tax Provision
107,781,000
85,013,000
-19,510,000
7,924,000
33,647,000
Net Income Common Stockholders
364,941,000
291,535,000
50,747,000
17,045,000
98,714,000
Diluted NI Available to Com Stockholders
364,941,000
291,535,000
50,747,000
17,045,000
98,714,000
Basic EPS
203.70
162.77
28.35
9.51
54.24
Diluted EPS
203.07
162.22
28.24
9.47
54.09
Basic Average Shares
1,791,523.57
1,791,105
1,790,205
1,793,276
1,820,019.33
Diluted Average Shares
1,797,320.71
1,797,116
1,797,159
1,799,660
1,825,061
Total Operating Income as Reported
472,492,000
382,633,000
41,039,000
25,518,000
133,029,000
Total Expenses
1,801,494,000
--
--
--
--
Net Income from Continuing & Discontinued Operation
364,941,000
291,535,000
50,747,000
17,045,000
98,714,000
Normalized Income
364,439,984.11
288,168,874
50,009,972.60
10,399,436.50
98,555,848
Interest Income
11,489,000
8,026,000
7,874,000
11,455,000
8,110,000
Interest Expense
11,295,000
14,072,000
17,677,000
12,005,000
8,779,000
Net Interest Income
194,000
-6,046,000
-9,803,000
-550,000
-669,000
EBIT
483,980,000
390,659,000
48,914,000
36,974,000
141,140,000
EBITDA
680,658,000
585,253,000
248,046,000
194,814,000
246,878,000
Reconciled Cost of Revenue
436,299,000
408,426,000
349,206,000
292,485,000
288,353,000
Reconciled Depreciation
196,678,000
194,594,000
199,132,000
157,840,000
105,738,000
Net Income from Continuing Operation Net Minority Interest
364,941,000
291,535,000
50,747,000
17,045,000
98,714,000
Total Unusual Items Excluding Goodwill
649,000
4,349,000
1,049,000
9,735,000
212,000
Total Unusual Items
649,000
4,349,000
1,049,000
9,735,000
212,000
Normalized EBITDA
680,009,000
580,904,000
246,997,000
185,079,000
246,666,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
147,984.11
982,874
311,972.60
3,089,436.50
53,848
3/31/2023 - 1/4/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: